Balak DM, Fallah Arani S, Hajdarbegovic E, et al. Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies. Br J Dermatol. 2016;175(2):250–62.

Article  CAS  PubMed  Google Scholar 

Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. The Lancet. 2019;394(10201):831–9.

Article  CAS  PubMed  Google Scholar 

Papp KA, Blauvelt A, Puig L, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. 2023;89(6):1149–58.

Article  CAS  PubMed  Google Scholar 

Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749–59.

Article  PubMed  Google Scholar 

Warren RB, Carrascosa JM, Fumero E, et al. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial. J Eur Acad Dermatol Venereol. 2021;35(4):919–27.

Article  CAS  PubMed  Google Scholar 

Burgers LE, Raza K, van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis: definitions and supporting evidence: from old to new perspectives. RMD Open. 2019;5(1):e000870.

Article  PubMed  PubMed Central  Google Scholar 

van Vollenhoven R, Askanase AD, Bomback AS, et al. Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Sci Med. 2022;9(1):e000634.

Article  PubMed  PubMed Central  Google Scholar 

Eyerich K, Krueger J, Stahle M, et al. An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis. J Eur Acad Dermatol Venereol. 2024;38(5):e424–7.

Article  CAS  PubMed  Google Scholar 

Cheuk S, Wikén M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed AR, Kaveri S, Spigelman Z. Long-term remissions in recalcitrant pemphigus vulgaris. N Engl J Med. 2015;373(27):2693–4.

Article  PubMed  Google Scholar 

Muller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. N Engl J Med. 2024;390(8):687–700.

Article  PubMed  Google Scholar 

Martini M, Corsi A, Agolini S, et al. High long-term efficacy of venom immunotherapy after discontinuation. Allergy. 2020;75(7):1793–6.

Article  PubMed  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11–22.

Article  CAS  PubMed  Google Scholar 

Pang Y, Khatri A, Suleiman AA, Othman AA. Clinical pharmacokinetics and pharmacodynamics of risankizumab in psoriasis patients. Clin Pharmacokinet. 2020;59(3):311–26.

Article  CAS  PubMed  Google Scholar 

Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304–15.

Article  CAS  PubMed  Google Scholar 

Bagit A, Maliyar K, Mansour M, et al. Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study. J Eur Acad Dermatol Venereol. 2025;39(5):e410–e412.

Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.

Article  CAS  PubMed  Google Scholar 

Krueger JG, Ferris LK, Menter A, et al. Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–24.e7.

Article  CAS  PubMed  Google Scholar 

Masson Regnault M, Konstantinou MP, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol. 2017;31(9):1491–6.

Article  CAS  PubMed  Google Scholar 

Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Angsana J, Yum N, et al. LB943 Prediction of super response and drug-free disease control in guselkumab patients using multivariate baseline serum biomarkers: data from part 3 of GUIDE trial. J Investig Dermatol. 2024;144(8 Suppl.):S165.

Article  Google Scholar 

Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–86.

Article  CAS  PubMed  Google Scholar 

Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006;142(7):836–42.

Article  CAS  PubMed  Google Scholar 

Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658–65.

Article  CAS  PubMed  Google Scholar 

Radakovic S, Seeber A, Hönigsmann H, Tanew A. Failure of short-term psoralen and ultraviolet A light maintenance treatment to prevent early relapse in patients with chronic recurring plaque-type psoriasis. Photodermatol Photoimmunol Photomed. 2009;25(2):90–3.

Article  PubMed  Google Scholar 

Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73.

Article  CAS  PubMed  Google Scholar 

Aronovich A, Novikov I, Pavlovsky L. Do biologic treatments for psoriasis lower the risk of psoriatic arthritis? A sytematic review. Am J Clin Dermatol. 2023;24(6):865–73.

Article  PubMed  Google Scholar 

Lerman JB, Joshi AA, Chaturvedi A, et al. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation. 2017;136(3):263–76.

Article  PubMed  PubMed Central  Google Scholar 

Piaserico S, Papadavid E, Cecere A, et al. Coronary microvascular dysfunction in asymptomatic patients with severe psoriasis. J Invest Dermatol. 2023;143(10):1929–36.e2.

Article  CAS  PubMed  Google Scholar 

Elnabawi YA, Oikonomou EK, Dey AK, et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol. 2019;4(9):885–91.

Article  PubMed  PubMed Central  Google Scholar 

Holzer G, Hoke M, Sabeti-Sandor S, et al. Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial. J Eur Acad Dermatol Venereol. 2021;35(2):441–9.

Article  CAS  PubMed